Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives

Antonio Marra¹, Sarat Chandarlapaty^{2

3

4}, Shanu Modi^{5

6}

Affiliations

¹ Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.
² Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Weill Cornell Medical College, New York, NY, USA.
⁵ Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. modis@mskcc.org.
⁶ Weill Cornell Medical College, New York, NY, USA. modis@mskcc.org.

Published Erratum

Antonio Marra et al. Nat Rev Clin Oncol. 2024 Sep.

. 2024 Sep;21(9):701.

doi: 10.1038/s41571-024-00933-8.

Antonio Marra¹, Sarat Chandarlapaty^{2

3

4}, Shanu Modi^{5

6}

¹ Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.
² Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Weill Cornell Medical College, New York, NY, USA.
⁵ Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. modis@mskcc.org.
⁶ Weill Cornell Medical College, New York, NY, USA. modis@mskcc.org.

No abstract available

Erratum for

Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
Marra A, Chandarlapaty S, Modi S. Marra A, et al. Nat Rev Clin Oncol. 2024 Mar;21(3):185-202. doi: 10.1038/s41571-023-00849-9. Epub 2024 Jan 8. Nat Rev Clin Oncol. 2024. PMID: 38191924 Free PMC article. Review.